
|Articles|October 26, 2006
Pfizer Purchases PowderMed
Author(s)BioPharm International Editors
Pfizer has agreed to purchase PowderMed (London, England, www.powdermed.com), a British company that develops DNA-based vaccines.
Advertisement
Pfizer has agreed to purchase PowderMed (London, England,
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Priority Review of Subcutaneous Lecanemab Signals Shift in Alzheimer’s Treatment Delivery
2
FDA Fast Tracks Innovent’s Trispecific Antibody for Multiple Myeloma
3
HanchorBio–WuXi Biologics Partnership Targets Fusion Protein Development Challenges
4
GSK’s Arexvy Gains EU Approval for Adults Aged 18 Years and Older
5




